Penumbra, Inc. (PEN) Dividend History

Company News

• Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

  Penumbra reported strong Q1 2025 earnings, with sales and thrombectomy revenue growth exceeding expectations. The company is well-insulated from tariff dynamics, with most of its manufacturing and raw materials sourced domestically. Analysts see further upside potential as the company executes on its growth strategy.

  Benzinga
• Exploring the Future of Virtual Reality: Market Overview, Trends, Analysis & Key Players

  The virtual reality (VR) market is experiencing robust growth, driven by advancements in technology and broader adoption across various sectors, including gaming, education, healthcare, and enterprise. Standalone VR headsets are gaining popularity due to their convenience and mobility, while improvements in AI and haptic feedback are enhancing the user experience.

  GlobeNewswire Inc.

  Featured Companies: MSFT U
• Why Penumbra Stock Zoomed 4% Higher Today

  Penumbra, a medical device company, has completed enrollment for a clinical trial of its latest thrombectomy product. An analyst at Truist Securities has also raised the company's price target, citing Penumbra's strong position in the neurological, venous, and thrombectomy segment.

  The Motley Fool
• Penumbra CEO Adam Elsesser sells shares worth over $3 million - Investing.com

  Penumbra CEO Adam Elsesser sold 15,000 shares worth over $3 million, representing a portion of his holdings in the company. The transactions were carried out under a pre-arranged trading plan.

  Investing.com
• Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  Zacks Investment Research